We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

Product News   Jun 17, 2019

 
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

Chris Torrance, PhoreMost’s CEO

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Updates to SureSeq™ NGS Portfolio Include Translocation and Partial Tandem Duplication Detection

Product News

Oxford Gene Technology has announced the addition of accurate detection capabilities for translocations and difficult-to-sequence partial tandem duplications (PTDs) in its myPanel™ customizable SureSeq™ NGS panels.

READ MORE

Neoantigen Specific Peptide Synthesis Service for Precision Immuno-oncology Therapeutic Development

Product News

The new service from GenScript aims to overcome the challenges of manufacturing difficult neoantigen peptides critical to personalized cancer vaccine and T-cell therapy generation.

READ MORE

Success in Next Phase of Open Source Malaria Initiative

Product News

Optibrium™ and Intellegens™ have successfully completed phase 2 of a global challenge aimed at developing and testing novel antimalarial compounds.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE